interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Vortioxetine Hydrobromide

Generic competition · all medicines · read 12 November 2026

Is there a generic of Vortioxetine Hydrobromide, and who makes it?

Vortioxetine Hydrobromide appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Vortioxetine Hydrobromide1 dosage-form group in the Orange Book
0generic makers listed
  1. Vortioxetine Hydrobromide appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Trintellix. No generic is listed as marketed.

20102015202020252030203501brand 2013data datePatent 7144884*PED listed to expire 17 December 2026Patent 9227946 listed to expire 15 June 2027Patent 9861630 listed to expire 15 June 2027Patent 9125908 listed to expire 15 June 2027Patent 9125910 listed to expire 15 June 2027Patent 9125909 listed to expire 15 June 2027Patent 11458134 listed to expire 15 June 2027Patent 8969355 listed to expire 15 June 2027Patent 8969355*PED listed to expire 15 December 2027Patent 9227946*PED listed to expire 15 December 2027Patent 9125908*PED listed to expire 15 December 2027Patent 9125909*PED listed to expire 15 December 2027Patent 9125910*PED listed to expire 15 December 2027Patent 9861630*PED listed to expire 15 December 2027Patent 11458134*PED listed to expire 15 December 2027Patent 8722684 listed to expire 30 June 2031Patent 8722684*PED listed to expire 30 December 2031Patent 9278096 listed to expire 21 March 2032Patent 9278096*PED listed to expire 21 September 2032Exclusivity PED to 23 February 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 23 February 2027Exclusivity PED Trintellix
  • 17 December 2026Patent 7144884*PED
  • 15 June 2027Patent 9227946
  • 15 June 2027Patent 9861630
  • 15 June 2027Patent 9125908
  • 15 June 2027Patent 9125910
  • 15 June 2027Patent 9125909
  • 15 June 2027Patent 11458134 drug product
  • 15 June 2027Patent 8969355

11 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.